激素性股骨头坏死易感基因的研究进展

张聪敏, 任凯迪, 张绮雯, 杨晶

中国药学杂志 ›› 2022, Vol. 57 ›› Issue (2) : 85-89.

PDF(1074 KB)
中国药学杂志
PDF(1074 KB)
中国药学杂志 ›› 2022, Vol. 57 ›› Issue (2) : 85-89. DOI: 10.11669/cpj.2022.02.001
综述

激素性股骨头坏死易感基因的研究进展

  • 张聪敏1,2, 任凯迪1,2, 张绮雯1,2, 杨晶1,2*
作者信息 +

Genetic Variations Associated with Glucocorticoid-Induced Osteonecrosis of the Femoral Head

  • ZHANG Cong-min1,2, REN Kai-di1,2, ZHANG Qi-wen1,2, YANG Jing1,2*
Author information +
文章历史 +

摘要

糖皮质激素类药物应用广泛,但长期或大剂量使用易发生严重的不良反应,其中激素诱导性股骨头坏死(steroid-induced osteonecrosis of femoral head,SONFH)因骨细胞和骨髓渐进性坏死,最终导致股骨头结构改变及塌陷,致残率高,严重降低患者的生活质量。目前SONFH的预防和治疗手段有限,且发生机制尚不清楚。近年来发现SONFH的发生与血液凝溶系统、脂质代谢、药物代谢转运系统等相关基因的遗传多态性密切相关。本研究通过综述近年来与SONFH相关的基因组学研究,为筛选SONFH的易感人群提供重要的遗传学参考,为SONFH的预防和治疗提供可能的靶点。

Abstract

Glucocorticoids are widely used in clinic, whereas there are severe adverse reactions in association with the long-term or high-dose application of glucocorticoids. Steroid-induced osteonecrosis of femoral head (SONFH) characterized by progressive necrosis of bone cells and bone marrow results in structural changes and collapse of the femoral head, and eventually leads to high disability rate and a poor quality of life. Up to now, the pathogenesis of SONFH is unclear, moreover the means of prevention and treatment are limited. In recent years, it has been found that the occurrence of SONFH is closely related to genetic polymorphism involved in blood coagulation system, lipid metabolism, drug metabolism and transport system. This review presents a summary of studies of SONFH in genomics to provide critical genetic information for screening the populations who are more prone to suffer SONFH, and offer possible targets for prevention and treatment of SONFH.

关键词

糖皮质激素 / 股骨头坏死 / 易感基因 / 激素诱导性股骨头坏死 / 基因多态性

Key words

glucocorticoid / osteonecrosis of the femoral head / susceptibility gene / steroid-induced osteonecrosis of femoral head / gene polymorphism

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
张聪敏, 任凯迪, 张绮雯, 杨晶. 激素性股骨头坏死易感基因的研究进展[J]. 中国药学杂志, 2022, 57(2): 85-89 https://doi.org/10.11669/cpj.2022.02.001
ZHANG Cong-min, REN Kai-di, ZHANG Qi-wen, YANG Jing. Genetic Variations Associated with Glucocorticoid-Induced Osteonecrosis of the Femoral Head[J]. Chinese Pharmaceutical Journal, 2022, 57(2): 85-89 https://doi.org/10.11669/cpj.2022.02.001
中图分类号： R965   

参考文献

[1] SCOTT D A, WOODS B, THOMPSON J C, et al. Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Pulm Med, 2015, 15: 145.
[2] LUO P, GAO F, HAN J, et al. The role of autophagy in steroid necrosis of the femoral head: a comprehensive research review. Int Orthop, 2018, 42(7):1747-1753.
[3] KERACHIAN M A, SEGUIN C, HARVEY E J. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol, 2009, 114(3-5):121-128.
[4] ZHAO D W, YU M, HU K, et al. Prevalence of nontraumatic osteonecrosis of the femoral head and its associated risk factors in the Chinese population: results from a nationally representative survey. Chin Med J (Engl), 2015, 128(21):2843-2850.
[5] CUI L, ZHUANG Q, LIN J, et al. Multicentric epidemiologic study on six thousand three hundred and ninety five cases of femoral head osteonecrosis in China. Int Orthop, 2016, 40(2):267-276.
[6] TANG C, CHEN L, GU W, et al. Cyclosporin a enhances the ability of trophoblasts to displace the activated human umbilical vein endothelial cell monolayers. Int J Clin Exp Pathol, 2013, 6(11):2441-2450.
[7] HADJIGEORGIOU G, DARDIOTIS E, DARDIOTI M, et al. Genetic association studies in osteonecrosis of the femoral head: mini review of the literature. Skelet Radiol, 2008, 37(1):1-7.
[8] LEE Y J, LEE J S, KANG E H, et al. Vascular endothelial growth factor polymorphisms in patients with steroid-induced femoral head osteonecrosis. J Orthop Res, 2012, 30(1):21-27.
[9] LIU Y, ZHANG Z, LIU S, et al. Association between VEGF-634G/C polymorphism and osteonecrosis of the femoral head susceptibility: a meta analysis. Int J Clin Exp Med, 2015, 8(7):10979-10985.
[10] MA W, XIN K, CHEN K, et al. Relationship of common variants in VEGFA gene with osteonecrosis of the femoral head: a Han Chinese population based association study. Sci Rep, 2018, 8(1):16221.
[11] SUN W, LI Z, SHI Z, et al. Relationship between post-SARS osteonecrosis and PAI-1 4G/5G gene polymorphisms. Eur J Orthop Surg Traumatol, 2014, 24(4):525-529.
[12] FERRARI P, SCHROEDER V, ANDERSON S, et al. Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation, 2002, 74(8):1147-1152.
[13] YANG J, JING M, YANG X. Association between genetic polymorphisms and osteonecrosis in steroid treatment populations: a detailed stratified and dose-response meta-analysis. Biosci Rep, 2019, 39(5):BSR20190024.
[14] CHAI W, ZHANG Z, NI M, et al. Genetic association between methylenetetrahydrofolate reductase gene polymorphism and risk of osteonecrosis of the femoral head. Biomed Res Int, 2015, 2015: 196495.
[15] SHANG X F, SU H, CHANG W W, et al. Association between MTHFR C677T polymorphism and osteonecrosis of the femoral head: a meta-analysis. Mol Biol Rep, 2012, 39(6):7089-7094.
[16] ZHU C H, GONG C Y, JIANG L, et al. Genetic polymorphism for steroid-induced osteonecrosis of the femoral head: a Meta-analysis. Chin J Mod Appl Pharm (中国现代应用药学),2019,36(19):2436-2444.
[17] ALBRECHT E W, STEGEMAN C A, HEERINGA P, et al. Protective role of endothelial nitric oxide synthase. J Pathol, 2003, 199(1):8-17.
[18] LU Y, YU Q, GUO W, et al. Effect of glucocorticoids on the function of microvascular endothelial cells in the human femoral head bone. Adv Clin Exp Med, 2020, 29(3):345-353.
[19] GAGALA J, BURACZYNSKA M, MAZURKIEWICZ T, et al. Endothelial nitric oxide synthase gene intron 4 polymorphism in non-traumatic osteonecrosis of the femoral head. Int Orthop, 2013, 37(7):1381-1385.
[20] ZHENG L, WANG W, NI J, et al. The association of eNOS gene polymorphism with avascular necrosis of femoral head. PLoS One, 2014, 9(2):e87583.
[21] KIM H S, BAE S C, KIM T H, et al. Endothelial nitric oxide synthase gene polymorphisms and the risk of osteonecrosis of the femoral head in systemic lupus erythematosus. Int Orthop, 2013, 37(11):2289-2296.
[22] JUSTESEN J, STENDERUP K, EBBESEN E N, et al. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology, 2001, 2(3):165-171.
[23] HIRATA T, FUJIOKA M, TAKAHASHI K A, et al. ApoB C7623T polymorphism predicts risk for steroid-induced osteonecrosis of the femoral head after renal transplantation. J Orthop Sci, 2007, 12(3):199-206.
[24] CUI Y, KAISAIERJIANG A, CAO P, et al. Association of apolipoprotein A5 genetic polymo rphisms with steroid-induced osteonecrosis of femoral head in a Chinese Han population. Diagn Pathol, 2014, 9: 229.
[25] XIAO M, WANG X, CHEN W. The clinical translational potential of p53-related alterations as cancer biomarkers. Histol Histopathol, 2015, 30(10):11637.
[26] YI J, LUO J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta, 2010, 1804(8):1684-1689.
[27] HOBAN D B, HOWARD L, DOWD E. GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease. Neuroscience, 2015, 303: 402-411.
[28] BENDER T S, MIGLIORE M M, CAMPBELL R B, et al. Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats. Neuroscience, 2015, 303: 569-576.
[29] LI S, WANG J. Salvianolic acid B prevents steroid-induced osteonecrosis of the femoral head via PPARγ expression in rats. Exp Ther Med, 2016, 13(2):651-656.
[30] HUANG Z, CHENG C, CAO B, et al. Icariin protects against glucocorticoid-induced osteonecrosis of the femoral head in rats. Cell Physiol Biochem, 2018,50(4):694-706.
[31] SONG Y, DU Z, REN M, et al. Association of gene variants of transcription factors PPARγ, RUNX2, Osterix genes and COL2A1, IGFBP3 genes with the development of osteonecrosis of the femoral head in Chinese population. Bone, 2017, 101: 104-112.
[32] WYLES C C, PARADISE C R, HOUDEK M T, et al. CORR(R) ORS richard A. brand award: disruption in peroxisome proliferator-activated receptor-gamma (PPARG) increases osteonecrosis risk through genetic variance and pharmacologic modulation. Clin Orthop Relat Res, 2019, 477(8):1800-1812.
[33] TOKUHARA Y, WAKITANI S, ODA Y, et al. Low levels of steroid-metabolizing hepatic enzyme (cytochrome P450 3A) activity may elevate responsiveness to steroids and may increase risk of steroid-induced osteonecrosis even with low glucocorticoid dose. J Orthop Sci, 2009, 14(6):794-800.
[34] MASADA T, IWAKIRI K, ODA Y, et al. Increased hepatic cytochrome P4503A activity decreases the risk of developing steroid-induced osteonecrosis in a rabbit model. J Orthop Res, 2008, 26(1):91-95.
[35] GUO F Q, DENG M. Correlation between steroid-induced osteonecrosis of the femoral head and hepatic CYP3A activity: a systematic review and meta-analysis. J Invest Surg, 2019, 32(2):118-126.
[36] HSIEH K P, LIN Y Y, CHENG C L, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos, 2001, 29(3):268-273.
[37] WANG Y, LI X L, GAO Y Y, et al. Genetic polymorphisms of CYP3A4 among chinese patients with steroid-induced osteonecrosis of the femoral head. Medicine, 2016, 95(44):e5332.
[38] HUANG R, ZHAN Q, HU W, et al. Association of ABCB1 and CYP450 gene polymorphisms and their DNA methylation status with steroid-induced osteonecrosis of the femoral head in the Chinese population. Genet Test Mol Biomark, 2020, 24(12):789-797.
[39] SAKAEDA T, NAKAMURA T, OKUMURA K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull, 2002, 25(11):1391-1400.
[40] YANG X Y, XU D H. MDR1(ABCB1) gene polymorphisms associated with steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus. Pharmazie, 2007, 62(12):930-932.
[41] ASANO T, TAKAHASHI K A, FUJIOKA M, et al. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics, 2003, 13(11):675-682.
[42] ZHOU Z, HUA Y, LIU J. Association of ABCB1/MDR1 polymorphisms in patients with glucocorticoid-induced osteonecrosis of the femoral head: Evidence for a meta-analysis. Gene, 2015, 569(1):34-40.
[43] YANG J, ZHANG A L, LU J L, et al. Correlation between ABCB1 C3435T and G2677T/A polymorphism and steroid-induced osteonecrosis of the femoral head: a Meta-analysis. Chin J Hosp Pharm(中国医院药学杂志), 2016,36(9):732-737.
[44] GONG L L, FANG L H, WANG H Y, et al. Genetic risk factors for glucocorticoid-induced osteonecrosis: a meta-analysis. Steroids, 2013, 78(4):401-408.
[45] TAMURA K, NAKAJIMA S, HIROTA Y, et al. Genetic association of a polymorphism of the cAMP-responsive element binding protein-binding protein with steroid-induced osteonecrosis after kidney transplantation. J B Miner Metab, 2007, 25(5):320-325.
[46] ZHAO Z, XUE Y, HONG D, et al. Polymorphisms in the glucocorticoid receptor gene and associations with glucocorticoid-induced avascular osteonecrosis of the femoral head. Genet Test Mol Biomark, 2017, 21(5):322-327.

基金

国家自然科学基金项目资助(81803638);河南省医学科技攻关计划联合共建项目资助(LHGJ20190269)

PDF(1074 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉